Lorlatinib and Bevacizumab Activity in ALK- Rearranged Lung Cancers After Lorlatinib Progression

JCO Precis Oncol. 2020 Nov 2:4:PO.20.00271. doi: 10.1200/PO.20.00271. eCollection 2020.

Authors

Noura J Choudhury¹, Robert J Young^{2

3}, Matthew Sellitti⁴, Alexandra Miller^{3

4}, Alexander Drilon^{1

3}

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
² Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
³ Weill Cornell Medical College, New York, NY.
⁴ Sloan Kettering Advanced Imaging Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY.

No abstract available

Publication types

Case Reports

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States